The blood-based DNA methylation analysis of Stubbe et al. also suggested SFRP1 as a promising independent predictive marker for survival in end stage pancreatic cancer patients treated with gemcitabine [27]. This evidence concerns the gene SFRP1 and familial pancreatic carcinoma.